IP Verse

Method Of Providing Pirfenidone Therapy To A Patient - EP3053580

The patent EP3053580 was granted to Intermune on Jun 30, 2021. The application was originally filed on Dec 18, 2007 under application number EP16151564A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3053580

INTERMUNE
Application Number
EP16151564A
Filing Date
Dec 18, 2007
Status
Granted And Under Opposition
May 28, 2021
Grant Date
Jun 30, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ZENTIVA KSMar 30, 2022ALTWITHDRAWN
GENERICS UKMar 29, 2022TER MEER STEINMEISTER & PARTNERWITHDRAWN
STADA ARZNEIMITTELMar 29, 2022HAMM & WITTKOPPWITHDRAWN
AERAMar 28, 2022AERAWITHDRAWN

Patent Citations (5) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
OPPOSITIONEP2124945
OPPOSITIONUS6253920
OPPOSITIONWO2007038315
OPPOSITIONWO2007064738
SEARCHWO2007064738

Non-Patent Literature (NPL) Citations (30) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- AZUMA, A. ET AL., AM JRESPIR CRIT CARE MED, (2005), vol. 171, pages 1040 - 47-
DESCRIPTION- CAIN ET AL., INT'L J IMMUNOPHARMACOLOGY, (1998), vol. 20, pages 685 - 695-
DESCRIPTION- ZHANG S ET AL., AUSTRALIAN AND NEW ENGLAND J OPHTHALMOLOGY, (1998), vol. 26, pages S74 - S76-
EXAMINATION- CHO MONIQUE E ET AL, "Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis.", CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY : CJASN SEP 2007, (200709), vol. 2, no. 5, ISSN 1555-905X, pages 906 - 913-
EXAMINATION- CHO MONIQUE E ET AL, "Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis.", MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, (200709), Database accession no. NLM17702727-
OPPOSITION- Anonymous, "History of Changes for Study: NCT00287716 Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis", ClinicalTrials.gov archive, (20060601), pages 1 - 6, XP055912682-
OPPOSITION- CAPACITY Results Conference Call-
OPPOSITION- "CHMP assessment report Esbriet International Nonproprietary Name: pirfenidone Procedure No. EMEA/H/C/002154", EMA/CHMP/115147/2011 Committee for Medicinal Products for Human Use (CHMP), (20101216), URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002154/WC500103073.pdf, (20150706), XP055200467-
OPPOSITION- Downie George, Mackenzie Jean, Williams Arthur, "Pharmacology and drug management for nurses", Chruchill Livingstone, (19990101), pages 1 - 17, XP055912828-
OPPOSITION- Intermune, "CAPACITY Results Conference Call", InterMune Presentation, (20090203), XP055332986-
OPPOSITION- Nagai Sonoko, Kunio Hamada, Michio Shigematsu, Masayosi Taniyama, Shitotomo Yamauchi, Takateru Izumi, "Open-label Compassionate Use One Year-treatment with Pirfenidone to Patients with Chronic Pulmonary Fibrosis", Internal Medicine, (20021201), vol. 41, no. 12, pages 1118 - 1123, XP055784040-
OPPOSITION- RAGHU G., ET AL., "TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS WITH A NEW ANTIFIBROTIC AGENT, PIRFENIDONE. RESULTS OF A PROSPECTIVE, OPEN-LABEL PHASE II STUDY.", American Journal of Respiratory and Critical Care Medicine, American Thoracic Society, US, US , (19990401), vol. 159., no. 04., ISSN 1073-449X, pages 1061 - 1069., XP000878900-
OPPOSITION- RAGHU G., ET AL., "TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS WITH A NEW ANTIFIBROTIC AGENT, PIRFENIDONE. RESULTS OF A PROSPECTIVE, OPEN-LABEL PHASE II STUDY.", American Journal of Respiratory and Critical Care Medicine, US , (19990401), vol. 159., no. 04., ISSN 1073-449X, pages 1061 - 1069., XP000878900-
OPPOSITION- Tozer Thomas N., Rowland Malcolm, "Introduction to Pharmacokinetics and Pharmacodynamics", Books, (20060101), pages 249 - 265, XP055912710-
OPPOSITION- Noble P W, Albera C, Bradford W Z, Costabel U, Glassberg M K, Kardatzke D, King T E , Lancaster L, Sahn S A, Szwarcberg J, Valeyre D, du Bois R M, "Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20110521), vol. 377, no. 9779, doi:10.1016/S0140-6736(11)60405-4., ISSN 0140-6736, pages 1760 - 1769, XP002731535
OPPOSITION- Smith Dorothy L., "Compliance Packaging: A Patient Education Tool", AMERICAN PHARMACY., DC., (19890201), vol. 29, no. 2, doi:10.1016/S0160-3450(15)31856-0, ISSN 0160-3450, pages 42 - 53, XP055912834
OPPOSITION- AZUMA ARATA ET AL, "Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.", American Journal of Respiratory and Critical Care Medicine, American Thoracic Society, US, US , (20050501), vol. 171, no. 9, doi:10.1164/rccm.200404-571OC, ISSN 1073-449X, pages 1040 - 1047, XP002476129
OPPOSITION- AZUMA ARATA ET AL, "Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.", American Journal of Respiratory and Critical Care Medicine, US , (20050501), vol. 171, no. 9, doi:10.1164/rccm.200404-571OC, ISSN 1073-449X, pages 1040 - 1047, XP002476129
OPPOSITION- Bowen James D et al, "Open-label study of pirfenidone in patients with progressive forms of multiple sclerosis", Multiple Sclerosis Journal, US , (20030601), vol. 9, no. 3, doi:10.1191/1352458503ms907oa, ISSN 1352-4585, pages 280 - 283, XP009098524
OPPOSITION- Bowen James D; Maravilla Kenneth; Margolin Solomon B, "Open-label study of pirfenidone in patients with progressive forms of multiple sclerosis", Multiple Sclerosis Journal, Sage, US, US , (20030601), vol. 9, no. 3, doi:10.1191/1352458503ms907oa, ISSN 1352-4585, pages 280 - 283, XP009098524
OPPOSITION- Walker Jonathan E; et al, "A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis", Multiple Sclerosis Journal, US , (20050101), vol. 11, no. 2, doi:10.1191/1352458505ms1134oa, ISSN 1352-4585, pages 149 - 158, XP009098526
OPPOSITION- Walker Jonathan E; Giri Shri N; Margolin Solomon B, "A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis", Multiple Sclerosis Journal, Sage, US, US , (20050101), vol. 11, no. 2, doi:10.1191/1352458505ms1134oa, ISSN 1352-4585, pages 149 - 158, XP009098526
OPPOSITION- BABOVIC-VUKSANOVIC D ET AL, "Phase II trial of pirfenidone in adults with neurofibromatosis type 1.", Neurology, Lippincott Williams & Wilkins , Philadelphia, US, US , (20061128), vol. 67, no. 10, doi:10.1212/01.wnl.0000243231.12248.67, ISSN 0028-3878, pages 1860 - 1862, XP002476128
OPPOSITION- BABOVIC-VUKSANOVIC D ET AL, "Phase II trial of pirfenidone in adults with neurofibromatosis type 1.", Neurology, US , (20061128), vol. 67, no. 10, doi:10.1212/01.wnl.0000243231.12248.67, ISSN 0028-3878, pages 1860 - 1862, XP002476128
OPPOSITION- Sabina A Antoniu, "`Pirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis", Expert Opinion on Investigational Drugs, Informa Healthcare, UK, UK , (20060701), vol. 15, doi:10.1517/13543784.15.7.823, ISSN 1354-3784, pages 823 - 828, XP008153421
OPPOSITION- M. E. Cho, Smith D. C., Branton M. H., Penzak S. R., Kopp J. B., "Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental Glomerulosclerosis", Clinical Journal of the American Society of Nephrology, (20070101), vol. 2, no. 5, doi:10.2215/CJN.01050207, ISSN 1555-9041, pages 906 - 913, XP055345280
SEARCH- RAGHU G ET AL, "TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS WITH A NEW ANTIFIBROTIC AGENT, PIRFENIDONE. RESULTS OF A PROSPECTIVE, OPEN-LABEL PHASE II STUDY", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, AMERICAN LUNG ASSOCIATION, NEW YORK, NY, US, (19990401), vol. 159, no. 4, ISSN 1073-449X, pages 1061 - 1069, XP000878900 [I] 1-15 * page 1062, column l, paragraph l * * page 1066, paragraph 1 * [Y] 1-15-
SEARCH- AZUMA ARATA ET AL, "Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 1 MAY 2005, (20050501), vol. 171, no. 9, ISSN 1073-449X, pages 1040 - 1047, XP002476129 [YD] 1-15 * page 1042, paragraph 2 *
SEARCH- BOWEN JAMES D ET AL, "Open-label study of pirfenidone in patients with progressive forms of multiple sclerosis.", MULTIPLE SCLEROSIS, (200306), vol. 9, no. 3, ISSN 1352-4585, pages 280 - 283, XP009098524 [Y] 1-15 * page 282, column L, paragraph 4 *
SEARCH- BABOVIC-VUKSANOVIC D ET AL, "Phase II trial of pirfenidone in adults with neurofibromatosis type 1.", NEUROLOGY 28 NOV 2006, (20061128), vol. 67, no. 10, ISSN 1526-632X, pages 1860 - 1862, XP002476128 [Y] 1-15 * page 1860, column R, paragraph 2 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents